Gene defect as a potential gateway for targeted prostate cancer therapy

The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy, report scientists.

Read the whole article on Science Daily

More from Science Daily